Leflunomide monotherapy in patients with early rheumatoid arthritis: Results of the Russian national Arava mono study

Балабанова, Римма Михайловна; Олюнин, Юрий Алексанрович

doi:10.14412/1995-4484-2012-703

Cited by 3 publications

(4 citation statements)

References 12 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Максимальная частота НЯ на фоне терапии элафрой регистрировалась в ранние сроки: через 4 нед НЯ отмечены у 6,5% больных 1-й группы и у 9,9% больных 2-й группы без необходимости отмены препарата. Примерно такая же частота НЯ отмечалась в отечественных исследованиях аравы [20,28,29]. При продолжении лечения элафрой частота НЯ снижалась.…”

Section: результаты и обсуждениеunclassified

See 1 more Smart Citation

Evaluation of the Efficacy and Tolerability of Leflunomide (Elafra) in Patients With Rheumatoid Arthritis According to the Data of an Open-Label Multicenter Study

Chichasova¹

2018

rsp

View full text Add to dashboard Cite

In accordance with international and Russian guidelines for the management of patients with rheumatoid arthritis (RA), after its diagnosis, a synthetic disease-modifying antirheumatic drug is prescribed, among these drugs, methotrexate is anchor and, when the latter is impossible to use, leflunomide is commonly administered. Objective: to evaluate the efficacy and safety of a leflunomide generic (Elafra) during a multicenter follow-up. Subjects and methods. The investigation enrolled 347 patients aged over 18 years who met the 2010 ACR/EULAR criteria for RA, had its duration of less and more than 2 years, signed informed consent, and followed up in 29 centers of Russia. Elafra was prescribed at a saturating dose of 100 mg for the first 3 days, then 20 mg/day. There might be a temporary two-fold reduction in the dose when adverse events (AE) occurred. The patients were examined before and 4, 12 and 24 weeks after beginning leflunomide treatment. The treatment efficiency was evaluated with DAS28 and CDAI and by the physician global assessment. Results and discussion. The patients were divided into two groups: 1) 125 patients with RA of less than 2 years’ duration and 2) 222 patients with RA of more than 2 years’ duration. The mean age of patients in Group 1 was 48.7±12.9 years; that in Group 2 was 52.5±11.95 years; the mean disease duration was 11.9±7.8 and 90.99±54.28 months, respectively. During 24-week treatment, there was a highly significant decrease in all assessed clinical, laboratory parameters and indices of RA activity in both groups. At 4 weeks of treatment, the effect was observed in 91.8% of the patients in Group 1 and in 84.6% in Group 2, whereas at 12 weeks the effect was noted in almost all patients (99.1% and 96.9% in Groups 1 and 2, respectively). The highest rate of AE during Elafra therapy was recorded in the early periods: at 4 weeks, AE were noted in 6.5% of the patients in Group 1 and in 9.9% in Group 2, without needing to discontinue the drug. Treatment continuation decreased the rate of AE. Because of its intolerance, Elafra was discontinued due to in one case in Group 1 (diarrhea at 24 weeks of treatment) and in 6 cases in Group 2 (at 12 and 24 weeks of treatment). Conclusion. Treatment with leflunomide (Elafra) leads to the rapid development of its effect in early and late RA in most patients and is characterized by a good tolerability.

show abstract

Section: результаты и обсуждениеunclassified

“…Балабановой и соавт. [28], как и в нашем исследовании, применение насыщающей дозы не приводило к увеличению числа НЯ.…”

Section: результаты и обсуждениеunclassified

Evaluation of the Efficacy and Tolerability of Leflunomide (Elafra) in Patients With Rheumatoid Arthritis According to the Data of an Open-Label Multicenter Study

Chichasova¹

2018

rsp

View full text Add to dashboard Cite

show abstract

“…The prevalence of patients with RA reaches 1% and the economic loss of society is comparable to those of coronary heart disease [7,8] there are 2-3 times more women with RA than men. The disease can begin in any period of life, but most often it strikes people of working age [9,10].…”

Section: Introductionmentioning

confidence: 99%

Rheumatoid Arthritis and Gastroduodenal Damage (Retrospective Analysis)

Tukhtaeva

Karimov²,

Abdullaev

et al. 2016

BJMMR

View full text Add to dashboard Cite

This work was carried out in collaboration between all authors. Author NKT designed the study, wrote the protocol, performed data collection; wrote the initial manuscript and revisions. Author BSA performed the literature review, data analysis and processing, manuscript writing, edition and revisions. Author MSK helped with the writing of the manuscript. Author IRM helped with the statistical analysis. Author MVS edited the manuscript and revisions. All authors read and approved the final manuscript.

show abstract

“…Достоверное улучшение по DAS28 отмечалось у 84,6% больных и примерно с одинаковой частотой регистрировалось у лиц, получавших и не получавших ранее БПВП. Хорошая переносимость стандартной схемы с применением высоких доз в начале лечения констатирована и в ходе анализа предварительных результатов назначения ЛФ при раннем РА, полученных в 20 медицинских центрах России [12].…”

unclassified

Leflunomide in clinical practice

Олюнин¹

2014

Modern Rheumatology Journal

View full text Add to dashboard Cite

Традиционная базисная терапия является основой лечения ревматоидного артрита (РА). Она остается методом выбора для больных, не получавших ранее базисных противовоспалительных препаратов (БПВП), и рассматривается как необходимый компонент комбинированного лечения. Выбор синтетических БПВП сравнительно невелик, и одним из наиболее перспективных на сегодняшний день представляется лефлуномид (ЛЕФ). Клинические исследования ЛЕФ при РА начались в середине 90-х годов. Позднее ЛЕФ широко применялся в практическом здравоохранении и зарекомендовал себя как один из лучших препаратов своего класса. В международных и национальных рекомендациях по лечению РА он рассматривается как один из основных компонентов комплексной терапии, который может назначаться на любой стадии заболевания в качестве единственного БПВП, а также в комбинации с другими противоревматическими средствами, включая синтетические БПВП и генно-инженерные биологические препараты.

show abstract

Leflunomide monotherapy in patients with early rheumatoid arthritis: Results of the Russian national Arava mono study

Abstract: О р и г и н а л ь н ы е и с с л е д о в а н и я

Cited by 3 publications

References 12 publications

Evaluation of the Efficacy and Tolerability of Leflunomide (Elafra) in Patients With Rheumatoid Arthritis According to the Data of an Open-Label Multicenter Study

Evaluation of the Efficacy and Tolerability of Leflunomide (Elafra) in Patients With Rheumatoid Arthritis According to the Data of an Open-Label Multicenter Study

Rheumatoid Arthritis and Gastroduodenal Damage (Retrospective Analysis)

Leflunomide in clinical practice

Contact Info

Product

Resources

About